IMMX
insider transactionsImmix Biopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
6.2K sh
Own +31%
-
Grant·A
Gabriel S Morris KEY
CFO, President
$0
500.0K sh
Own New
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
6.2K sh
Own +14%
-
Grant·A
Ilya M Rachman KEY
CEO and Chairman
$0
500.0K sh
Own New
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
6.2K sh
Own +1%
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
6.2K sh
Own New
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
6.2K sh
Own +28%
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
6.2K sh
Own +4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | Carey Ng | Grant A | 12.5K | $0 |
| May 22, 2026 | Carey Ng | Grant A | 6.2K | $0 |
| May 22, 2026 | Gabriel S Morris KEY | Grant A | 500.0K | $0 |
| May 22, 2026 | Magda Marquet | Grant A | 12.5K | $0 |
| May 22, 2026 | Magda Marquet | Grant A | 6.2K | $0 |
| May 22, 2026 | Ilya M Rachman KEY | Grant A | 500.0K | $0 |
| May 22, 2026 | Jason Hsu | Grant A | 12.5K | $0 |
| May 22, 2026 | Jason Hsu | Grant A | 6.2K | $0 |
| May 22, 2026 | Yekaterina Chudnovsky | Grant A | 12.5K | $0 |
| May 22, 2026 | Yekaterina Chudnovsky | Grant A | 6.2K | $0 |
| May 22, 2026 | Jane Buchan | Grant A | 12.5K | $0 |
| May 22, 2026 | Jane Buchan | Grant A | 6.2K | $0 |
| May 22, 2026 | Helen C. Adams | Grant A | 12.5K | $0 |
| May 22, 2026 | Helen C. Adams | Grant A | 6.2K | $0 |
About IMMX insider trading
This page tracks insider transactions for Immix Biopharma, Inc. (IMMX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.